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Abstract
Background: Increasingly, women elect breast reconstruction after mastectomy. However, their expectations of
surgery are often not met, and dissatisfaction with outcome and ongoing psychosocial concerns and distress are
common. We developed a patient-centered intervention, PEGASUS:(Patients’ Expectations and Goals: Assisting
Shared Understanding of Surgery) which supports shared decision making by helping women clarify their own,
individual goals about reconstruction so that they can discuss these with their surgeon. Our acceptability/feasibility
work has shown it is well received by patients and health professionals alike. We now need to establish whether
PEGASUS improves patients’ experiences of breast reconstruction decision making and outcomes. The purpose of
this study is, therefore, to examine the effectiveness of PEGASUS, an intervention designed to support shared
decision making about breast reconstruction.
Methods: A multi-centered sequential study will compare the impact of PEGASUS with usual care, in terms of
patient reported outcomes (self-reported satisfaction with the outcome of surgery, involvement in decision making
and in the consultation) and health economics. Initially we will collect data from our comparison (usual care) group
(90 women) who will complete standardized measures (Breast-Q, EQ5D -5 L and ICECAP- A) at the time of decision
making, 3, 6 and 12 months after surgery. Health professionals will then be trained to use PEGASUS, which will be
delivered to the intervention group (another 90 women completing the same measures at the time of decision
making, and 3, 6 and 12 months after surgery). Health professionals and a purposefully selected sample of
participants will be interviewed about whether their expectations of reconstruction were met, and their experiences
of PEGASUS (if appropriate).
Discussion: PEGASUS may have the potential to provide health professionals with an easily accessible tool aiming
to support shared decision making and improve patients’ satisfaction with breast reconstruction. Results of this
study will be available at the end of 2019.
Trial registration: ISRCTN 18000391 (DOI 10.1186/ISRCTN18000391) 27/01/2016.
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Background
Mastectomy can have a considerable, long-term psycho-
social impact for women worldwide. In England alone,
more than 15,000 women undergo mastectomy each
year and over 5000 elect breast reconstruction (BR) to
surgically recreate a breast shape [1]. Options regarding
BR timing and type are numerous, requiring women to
make complex decisions amidst the emotional upheaval
associated with cancer. Although BR aims to improve
quality of life and appearance concerns, a national audit
[1] reported worrying levels of dissatisfaction with surgi-
cal outcome, supporting previous reports of ongoing
pain [2] and scarring [3]. BR is not a panacea for the
distress of mastectomy [4] - almost half patients report
some regret [5].
Women seeking BR anticipate it will restore a sense of
‘normality’, but their expectations of outcomes are often
unclear [6, 7]. The decision is ‘preference-sensitive’ [8]
because the ‘right choice’ depends on individuals’ personal
preferences rather than generic treatment factors. Clarifying
each patient’s preferences and values is imperative, central
to shared decision making (SDM) [9] and key to patient-
centred care [10]. However, treatment decision making
often triggers breakdowns in communication between
patients and health professionals (HPs) [11]. Patients and
health professionals differ when rating the importance of
facts and goals guiding decisions about reconstruction [8].
Whilst women make choices by drawing comparisons with
their pre-cancer appearance, health professionals draw on
their clinical experience of a wider range of post-surgical
outcomes including appearance, pain, impact on physical
activities, body image and wellbeing.
Women dissatisfied with the outcome of BR may seek
further, corrective surgery (with implications for health-
care resources and distress for patients), and may main-
tain avoidance behaviours (e.g. intimacy, clothing
choices) that BR was intended to reduce [6]. We surmise
that if women have realistic expectations, then patient
dissatisfaction, well-being and requests for additional
surgery would improve. Although HPs need to ask
women about their priorities and concerns [8], promote
realistic expectations [12, 13], and support them making
high quality decisions by empowering them through
SDM [14], there are no interventions to help them elicit
patients’ values, expectations and preferences. Instead,
support typically focuses on information provision (e.g.
websites, leaflets). However, increasing the amount of
information available does not address erroneous expec-
tations since it reinforces patients as passive recipients
rather than actively engaged in setting clear, patient-
centred goals (an approach associated with positive
experiences and outcomes [15]. SDM has been heralded
as a means of improving patient reported outcomes and
satisfaction with cancer care [16] (particularly concerning
preference sensitive decisions [17]) but implementation is
difficult and slow [18]. Some decision aids for mastectomy
patients are available [19, 20] but these are not BR-specific
or focused around a face-to-face discussion centred on
patients’ individual needs and the practicalities and possi-
bilities of surgery. Nor do they explicitly help HPs and
patients with the challenge of implementing SDM in this
difficult and emotive situation. Clinicians report concerns
that online interventions such as BRESDEX.com cannot
be tailored to patients’ individual needs, and could replace
nurses’ roles and induce patient anxiety if not provided
under clinical supervision [20]. Recently, attention has
shifted to decision coaching to facilitate patients’ prepar-
ation for SDM about preference sensitive decisions [21].
We developed an intervention to facilitate SDM by
specifically helping patients and HPs clarify each
woman’s motivations for BR (PEGASUS: Patients’ Expec-
tations and Goals: Assisting Shared Understanding of
Surgery) which is designed to elicit each patient’s own
expectations of what she wants BR to achieve, facilitate
setting patient centred goals (what she considers a
successful outcome), and aid discussion of both physical
and psychosocial expectations, goals and outcomes with
their surgical team. PEGASUS is delivered to women
previously informed about their reconstructive options,
since physique and health status may render some pro-
cedures inappropriate. Unlike a purely paper-based
intervention [19], PEGASUS involves meeting a decision
facilitator (a specialist nurse/psychologist trained in its
use who is referred to as the PEGASUS Coach) during
which the patient is helped to identify her individual BR
goals, what would indicate a successful outcome and the
importance of each goal. She takes the completed
PEGASUS sheet into the surgical consultation where it
is used to inform shared goals and promote concordance
between the patient and surgeon, so they approach sur-
gical outcomes as a shared endeavour [22].
Interventions encouraging patients to prepare for and
actively engage in consultations effectively improve satis-
faction and health outcomes [23, 24]. PEGASUS facili-
tates the disclosure and discussion of expectations,
enabling the surgeon to decide the extent to which they
are realistic and, if necessary, take appropriate steps to
address unrealistic expectations (e.g. explain the likely
outcomes further, show more photographs). PEGASUS
is a novel, well-accepted intervention that helps women
express what they want and assist health professionals
‘diagnose’ their patients’ preferences – failure to do this
is common and warrants interventions to “transform the
role of patients in the NHS from passive users into
active and engaged partners in care” ([25] pviii). Our
work follows recommendations for developing and
evaluating complex interventions [26]. Feasibility and
acceptability testing is complete (conducted under NRES
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reference 11/NW/0788) and showed that PEGASUS is
acceptable to both patients and health professionals alike
[27]. We now need to establish whether using PEGASUS
offers benefits over usual care – this is the aim of the
current study.
Method
The main research question
 Is a patient-centred, goal-focussed intervention
(PEGASUS) that was developed to support shared
decision making (SDM) for women contemplating
breast reconstruction (BR) effective in terms of pa-
tient reported outcomes and costs?
Aims of the study
 To assess the efficacy of an intervention designed to:
◦ elicit patients’ expectations of what reconstructive
breast surgery will achieve
◦ facilitate setting of patient-centred goals
◦ facilitate discussion of these expectations and
goals with the patient’s surgical team.
 To explore whether the PEGASUS intervention
improves patient reported outcomes (Breast Q) and
reduces decisional conflict amongst women offered
the option of breast reconstruction.
 To explore the economic costs of delivering the
PEGASUS intervention compared with the costs of
treatment as usual.
 To explore patients’ and health professionals’
experiences of using the PEGASUS intervention and
its implementation within breast reconstruction
services.
The research will be overseen and informed by the
expertise of an advisory group consisting of patient rep-
resentatives, a surgeon, clinical psychologist, specialist
nurse, breast cancer charity representative and members
of the research team.
Design
A mixed methods (qualitative and quantitative methods),
multi-centred, non-randomised between subjects, before-
and-after design comparing usual care (control) with the
intervention (PEGASUS). Randomised Controlled Trials
(RCTs) are not necessarily suited for psychosocial research
[28]. In this study it is inappropriate to randomize partici-
pants since contamination effects between conditions are
likely if surgeons must focus some consultations around
the patient goals offered by PEGASUS, but revert to usual
care in others. In this non-randomised design, the control
group comprises consenting patients receiving usual care.
On completion of the control group recruitment, the health
professionals receive PEGASUS training, prior to interven-
tion group recruitment. Semi-structured interviews will be
conducted with a selection of participants and health pro-
fessionals involved in the PEGASUS intervention condition.
Intervention consultations will be recorded (with permis-
sion) and assessed against a study-specific checklist to
check the fidelity of the intervention.
Trial design characteristics
The characteristics of the PEGASUS trial were assessed
using PRECIS-2 [29]. PRECIS-2 is a tool specifically de-
signed to assess trial design on a continuum of pragmatic-
explanatory across nine criteria: eligibility, recruitment,
setting, organisation, flexibility delivery, flexibility adher-
ence, follow-up, primary outcome and primary analysis.
Pragmatic trials aim to explore whether an intervention
works in real-life settings whereas exploratory trials aim
to explore whether an intervention works under ideal con-
ditions [29, 30]. Figure 1 illustrates the trial design based
on the nine criteria. Eligibility, recruitment, setting,
follow-up and primary analysis follow a pragmatic ap-
proach, whereas organisation, flexibility delivery, flexibility
adherence and primary analysis fall along the pragmatic-
explanatory continuum.
Sites
Data collection will take place at hospital sites (Bristol,
Bath, Truro, Winchester, and Cardiff ) with comprehen-
sive breast reconstruction services. The researcher will
maintain weekly contact with each site, where clinic staff
will identify eligible participants, provide study informa-
tion and give the researcher the details of those who
consent to participate.
Sample size
One hundred eighty women over the age of 18 who have
been diagnosed with breast cancer or DCIS (Ductal
Carcinoma in Situ) or are seeking risk reducing surgery due
to a strong family history of breast cancer, and who are
considering breast reconstruction following mastectomy.
We will record how many women are eligible for the study,
how many participate and record reasons for refusal, where
possible.
Power calculations
The primary outcome measure is the Breast-Q (breast
reconstruction) [31] with psychosocial wellbeing, sexual
well-being, physical well-being and 5 satisfaction sub-
scales applicable pre- and post-op and an expectations
subscale applicable pre-operatively only. Sample size has
been determined to ensure the simple comparison
between the two groups 3–month post-operatively has
at least 90% power (beta <= .20) using contemporary
levels of significance (alpha = .05) in a two-sided test as
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this will ensure similar power requirements will be met
for within group comparisons and for the anticipated
interaction effect in the two-way ANOVA. An a priori
power analysis based on a two-sided application of the
independent samples t-test with an assumed lower esti-
mate of a medium effect size (Cohen’s d = 0.5) indicates
that at least 90% power would be achieved with a sample
size of n = 90 per group. This stated power equates to at
least 75% of women doing better in PEGASUS than they
would have done with treatment as usual.
Exclusion criteria
Women who, for any reason, are unsuitable for breast
reconstruction or unable to participate in an interven-
tion and study conducted in English will not be eligible
to participate. We acknowledge this limitation, but do not
currently have the resources needed to offer PEGASUS in
other languages. If this study is successful we will explore
its use with women with limited English proficiency (LEP)
in future research.
Intervention training
Specialist nurses, psychologists and surgeons at each site
will be trained to use PEGASUS by AC (the clinical
psychologist in the study team) and the study researcher
(NP). Face-to-face training will be supplemented by a
manual and video footage demonstrating its use, accessible
throughout the study. Feedback on this training (elicited in
the health professional interviews and questionnaires at the
training sessions) will identify whether edits are needed
prior to making training resources available through the
PEGASUS website (www.pegasusdecisionmaking.com) in
any subsequent roll-out of the intervention.
Procedure (see Additional file 1)
Potential participants will be identified by clinic staff at
each site from appropriate clinic lists.
At each participating site, the control group will be
recruited before recruitment to the intervention condition
begins. Staff will be trained in the use of the intervention
once control group recruitment has been completed at
their site.
Women identified as being eligible for the control
(usual care) group will be given the study information
sheet together with a consent form and questionnaire
booklet and a stamped – return addressed envelope.
Clinic staff will provide these materials and be on hand
to address any questions from potential participants
(and will contact the research team for assistance if there
are any questions they are unable to answer).
Women identified as being eligible for the interven-
tion group will be given the study information sheet,
and the opportunity to ask questions about the study.
Those interested in taking part will be given a consent
form and an appointment at which they will complete
the PEGASUS intervention - this appointment will be
not less than 24 h after they have first been told about
the study (exact details will depend on the specific
study site).
During the intervention consultation, women who
have chosen to take part in this study will have a discus-
sion with the trained PEGASUS coach that will be aimed
at clarifying their explicit goals and expectations about
reconstructive surgery. Together, the coach and patient
will complete the PEGASUS sheet – a single piece of
paper which will summarise the conversation and list
explicitly what the patient is hoping breast reconstruc-
tion will achieve. The participant will then take this
PEGASUS sheet into their consultation with the breast
reconstruction surgeon, who will have been trained to
use the sheet, to encourage a discussion about the
woman’s expectations, thereby framing the surgical dis-
cussion in terms of what it is that the patient is hoping
to achieve.
Fig. 1 PRECIS-2
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We will seek consent from women in the intervention
condition to record their PEGASUS consultations in
order that we can assess the fidelity of the intervention.
We will ask all participants to complete the following
self-report measures in the questionnaire booklet at
baseline (i.e. pre-intervention for those in the PEGASUS
condition, equivalent timing for those in the control
condition) and 3, 6 and 12 months after surgery,
together with visual analogue scales (VAS) to assess the
extent to which expectations/goals have been met, and
satisfaction with decision making and care. Measures
will be available for completion in paper format and
online. Statistical analysis will examine changes in the
self-report scores over time.
Measures
Primary outcome measure
Breast-Q (reconstruction or mastectomy versions, as appro-
priate) [31] is a widely used measure of quality of life specific
to breast reconstruction.
Secondary outcome measures
EQ-5D-5 L (a measure of health-related quality of life)
[32] and ICECAP-A [33] capabilities (what participants
want to be able to do in various key aspects of life),
shared decision making (Decisional Conflict scale [34],
CollaboRATE [35] and visual analogue scales) and
Decisional Regret (Decisional Regret Scale) [36].
Cost-utility analyses will be undertaken from a funder
perspective over the timeframe of the study. Resources
used at each stage of shared decision making will be
recorded using a study-specific resource use checklist
tool, which will be used with prices from published
sources to estimate unit costs. Costs will be expressed in
2017 prices and uprated in line with inflation. Funder
incremental costs (shared decision making with PEGASUS
versus usual care) will be related to incremental change in
EQ-5D-5 L scores to estimate (cost per Quality adjusted
Life Year gained):
• Cost per Quality-adjusted Life Year gained based on
the EQ5DL scores
• Average cost of implementing PEGASUS per site
• Average cost per patient
• Cost per hour of shared decision making
Analysis
The analyses will be described in detail in a full Statis-
tical Analysis Plan but, in brief, the design permits a
robust statistical analysis using a linear mixed model
with random intercepts for longitudinal data, a one-way
ANCOVA with baseline pre-op measure as a covariate,
and t-tests for prior reasoned group comparisons. An
adjusted ANCOVA will be used to account for the
between-subjects non-equivalent groups design and this
will prevent an overestimation of treatment effect due to
measurement error. Primary analyses will be performed
under multiple imputation using Multiply Imputed
Chained Equations (MICE) and repeated on a complete
basis. Data validity checks and missing values analysis
will be undertaken prior to descriptive and inferential
analysis. PEGASUS is intended for use with any surgical
group and we will compare delayed with immediate
reconstruction patients for any systematic differences
in outcome.
Interviews
We will conduct a nested qualitative study that will involve
semi-structured interviews with around 32 patients (8 per
site; 4 intervention, 4 control) and 20 health professionals
(PEGASUS Coaches and surgeons; 5 per site), exploring
experiences of PEGASUS (where appropriate), patients’
expectations of reconstruction and if these were met.
Patient interviews will be conducted around the 12 month
follow up data collection, using Breast-Q scores (high, mid-
dle, low) to purposefully sample to ensure interviews are
conducted with patients with varying outcomes. Telephone
interviews will be conducted if preferred by the patient or
health professional, or if face-to-face is not possible. Face-
to-face interviews will be conducted at a time and place of
the interviewee’s choosing (following standard University
protocols for safe lone working). Interview recordings will
be transcribed verbatim and subjected to thematic analysis
[37]. Findings will be agreed by the research team, with
feedback from the advisory group. Participants’ goals and
expectations on the PEGASUS forms will be subjected to
content analysis.
Data storage/confidentiality
A data protection document describes the study’s safe-
guards for the storage and protection of confidential infor-
mation, both held manually and on computers. This
document is guided by the Caldicott principles for handling
patient-identifiable information, The UK Data Protection
Act (1998) [38] and Good Clinical Practice guidance [39].
All data will be treated as confidential. Only members of
the research team who are also members of the breast
reconstruction service at the participating sites will examine
clinic and medical records in order to identify potential par-
ticipants. Once consented, the research team based at the
university may require access to participants’ medical
records in order to collect and check health economic data.
Permission to do this will be included on the participant
consent form. Audio files (interviews and consultation
recordings) and data will be stored on a password protected
computer accessible only by the research team. Completed
questionnaires and consent forms will be stored separately,
in a locked filing cabinet.
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Research governance, safety and the conduct of the
study
It was agreed that an independent data monitoring com-
mittee was not necessary and interim analyses will not
be conducted. A PEGASUS steering group will be set up
with an independent chair and members and will meet
every 6 months. The steering group will provide advice
and supervision of the study and will focus on the pro-
gress of the study, approaches to improve adherence, the
collection of follow-up data, participant safety and con-
sideration of new information. The management team
(consisting of the principle investigator, clinical psych-
ologist, researcher, health economist and statistician) will
meet once-a-month to discuss study progress, protocol
adherence and amendments for ethical approval. Access
to the final dataset will be restricted to members of the
study management group.
Dissemination of research findings
Members of our steering and management groups will
provide expert advice on the dissemination of the main
outcomes to participants. The findings of this study will
be disseminated via publications in peer-reviewed jour-
nals. Dissemination of the findings to health profes-
sionals and organisations supporting women with breast
cancer will be planned and developed with stakeholders
throughout the study.
Study approvals
This study has been approved by the NRES Committee
South Central - Berkshire B (reference 15/SC/0331) and the
Faculty of Health and Applied Sciences Research Ethics
Committee at the University of the West of England, Bristol.
All necessary R&D approvals have been granted by the NHS
study sites. The study has been accepted on the National
Institute for Health Research (NIHR) Clinical Research
Network (CRN) Portfolio.
Research Sponsor: University of the West of England,
Bristol.
Timeframe of the study
The trial started on the 1st of July 2015 and will be com-
pleted in June 2019.
Discussion
This study will establish whether the PEGASUS intervention
offers benefits over usual care for women offered the option
of breast reconstructive surgery. Since it focuses on each
patient’s individual, personal goals, PEGASUS offers a tool
to support health professionals who are looking to provide
patient-centred individualized care for women facing the
choice of whether or not to undergo breast reconstruction
of any sort and at any time (as an immediate or delayed
procedure). It is not limited to any particular type or timing
of reconstructive surgery since it is delivered after a patient
has been given information by her surgical team about the
particular procedures for which she is deemed to be a
suitable candidate. We will collate information about the
decisions women make about reconstructive surgery, as
well as details of their diagnosis and other treatment in
order to describe our sample.
This study does not employ randomization for the rea-
sons outlined above. Instead, we are employing a rigorous
design that is best suited to this specific clinical situation.
We plan future research to explore the acceptability and
feasibility of the PEGASUS intervention with other patient
groups, including adults seeking cosmetic surgical proce-
dures and young people with craniofacial conditions.
Additional file
Additional file 1: Flow chart of the PEGASUS trial. (DOCX 43 kb)
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